Clough Capital Partners’s Acceleron Pharma XLRN Stock Holding History

Clough Capital Partners’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-39,901	Closed	-$1.44M	–	208
2016 Q3	$1.44M	Sell	39,901 -3,300	-8%	-$109K	0.08%	126
2016 Q2	$1.47M	Sell	43,201 -24,796	-36%	-$806K	0.08%	134
2016 Q1	$1.79M	Sell	67,997 -139,900	-67%	-$4.07M	0.08%	140
2015 Q4	$10.1M	Sell	207,897 -2,700	-1%	-$97.2K	0.47%	73
2015 Q3	$5.24M	Sell	210,597 -336,053	-61%	-$10.1M	0.23%	94
2015 Q2	$17.3M	Buy	546,650 +34,220	+7%	+$1.1M	0.66%	54
2015 Q1	$19.5M	Buy	512,430 +97,833	+24%	+$3.89M	0.65%	66
2014 Q4	$16.2M	Buy	+414,597	New	+$14.4M	0.58%	69

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Clough Capital Partners's XLRN Position: Q4 2016 in Review

Clough Capital Partners sold out of Acceleron Pharma (XLRN) in Q4 2016, closing a stake of 39,901 shares — an estimated $1.44M sold.

Clough Capital Partners first reported a position in XLRN in Q4 2014 and held it in 8 quarters. The position peaked at $19.5M in Q1 2015. 146 funds tracked by Wall St. Rank hold XLRN as of Q4 2016.

Clough Capital Partners reported no remaining Acceleron Pharma position as of Q4 2016 after selling out during the quarter.
Clough Capital Partners sold 39,901 Acceleron Pharma shares in Q4 2016, an estimated $1.44M.
Clough Capital Partners first reported a position in Acceleron Pharma in Q4 2014 and held it in 8 quarters.
Clough Capital Partners's Acceleron Pharma position peaked at $19.5M in Q1 2015.
146 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2016.

Based on Clough Capital Partners's 13F filing for Q4 2016, filed 14 Feb 2017.